NPPA issued a notification regarding fixation of retail price of Empagliflozin 25 mg + Linagliptin 5 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release)' for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Macleods Pharmaceuticals Ltd. (Marketer)

Aug 14, 2026 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific ComplianceThe National Pharmaceutical Pricing Authority (NPPA) on August 11, 2026, issued a notification regarding fixation of retail price of Empagliflozin 25 mg + Linagliptin 5 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release)' for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Macleods Pharmaceuticals Ltd. (Marketer).

The following has been stated: -

•For each film coated bilayer tablet contains: Empagliflozin 25 mg + Linagliptin 5 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release)' for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Macleods Pharmaceuticals Ltd. (Marketer) the retail price is 12.27(Rs).

[Notification No.: 19(5274)/2026/DP/NPPA/Div.III/14939/2026]

 


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT